PMID- 32198311 OWN - NLM STAT- MEDLINE DCOM- 20210309 LR - 20210309 IS - 1535-5667 (Electronic) IS - 0161-5505 (Linking) VI - 61 IP - 11 DP - 2020 Nov TI - (18)F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria. PG - 1615-1620 LID - 10.2967/jnumed.120.241737 [doi] AB - Our purpose was to determine the effect of a smoothing filter and partial-volume correction (PVC) on measured prostate-specific membrane antigen (PSMA) activity in small metastatic lesions and to determine the impact of these changes on molecular imaging PSMA (miPSMA) scoring. Methods: Men who had biochemical recurrence of prostate cancer with negative findings on CT and bone scintigraphy were referred for (18)F-DCFPyL (2-(3-(1-carboxy-5-[(6-(18)F-fluoro-pyridine-3-carbonyl)-amino]-pentyl) PET/CT. Examinations were performed on 1 of 2 different brands of PET/CT scanner. All suspected tumor sites were manually contoured on coregistered CT and PET images, and each was assigned an miPSMA score as per the PROMISE criteria. The PVC factors were calculated for every lesion using the anatomic CT and then applied to the unsmoothed PET images. The miPSMA scores, with and without the corrections, were compared, and a simplified rule-of-thumb (RoT) correction factor (CF) was derived for lesions at various sizes (<4 mm, 4-7 mm, 7-9 mm, and 9-12 mm). This CF was then applied to the original dataset and the miPSMA scores that were obtained using the RoT CF were compared with those obtained using the actual corrections. Results: There were 75 men (median age, 69 y; median serum PSA, 3.69 mug/L) with 232 metastatic nodes less than 12 mm in diameter (mean lesion volume, 313.5 +/- 309.6 mm(3)). The mean SUV(max) before and after correction was 11.0 +/- 9.3 and 28.5 +/- 22.8, respectively (P < 0.00001). The mean CF for lesions smaller than 4 mm (n = 22), 4-7 mm (n = 140), 7-9 mm (n = 50), and 9-12 mm (n = 20) was 4 (range, 2.5-6.4), 2.8 (range, 1.6-4.9), 2.3 (range, 1.6-3.3), and 1.8 (range, 1.4-2.4), respectively. Overall, the miPSMA scores were concordant between the corrected dataset and the RoT dataset for 205 of 232 lesions (88.4%). Conclusion: A smoothing filter and PVC had a significant effect on measured PSMA activity in small nodal metastases, impacting the miPSMA score. CI - (c) 2020 by the Society of Nuclear Medicine and Molecular Imaging. FAU - Ortega, Claudia AU - Ortega C AD - Joint Department of Medical Imaging, Princess Margaret Hospital, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Schaefferkoetter, Josh AU - Schaefferkoetter J AD - Joint Department of Medical Imaging, Princess Margaret Hospital, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, Ontario, Canada. AD - Siemens Healthcare Limited, Oakville, Ontario, Canada. FAU - Veit-Haibach, Patrick AU - Veit-Haibach P AD - Joint Department of Medical Imaging, Princess Margaret Hospital, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Anconina, Reut AU - Anconina R AD - Joint Department of Medical Imaging, Princess Margaret Hospital, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, Ontario, Canada. FAU - Berlin, Alejandro AU - Berlin A AD - Radiation Medicine Program, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada; and. FAU - Perlis, Nathan AU - Perlis N AD - Urologic Oncology, University Health Network, Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, Ontario, Canada. FAU - Metser, Ur AU - Metser U AD - Joint Department of Medical Imaging, Princess Margaret Hospital, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, Ontario, Canada ur.metser@uhn.ca. LA - eng PT - Journal Article DEP - 20200320 PL - United States TA - J Nucl Med JT - Journal of nuclear medicine : official publication, Society of Nuclear Medicine JID - 0217410 RN - 0 (2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid) RN - 0 (Antigens, Surface) RN - 0 (Fluorine Radioisotopes) RN - 8W8T17847W (Urea) RN - EC 3.4.17.21 (FOLH1 protein, human) RN - EC 3.4.17.21 (Glutamate Carboxypeptidase II) RN - K3Z4F929H6 (Lysine) SB - IM MH - Aged MH - Aged, 80 and over MH - Antigens, Surface/*metabolism MH - *Fluorine Radioisotopes MH - Glutamate Carboxypeptidase II/*metabolism MH - Humans MH - Lysine/*analogs & derivatives MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/*diagnostic imaging MH - Positron Emission Tomography Computed Tomography/*methods MH - Prostatic Neoplasms/*diagnostic imaging/pathology MH - Urea/*analogs & derivatives OTO - NOTNLM OT - PET/CT OT - PSMA OT - genitourinary OT - partial-volume correction OT - prostate cancer OT - subclinical EDAT- 2020/03/22 06:00 MHDA- 2021/03/10 06:00 CRDT- 2020/03/22 06:00 PHST- 2020/01/06 00:00 [received] PHST- 2020/03/09 00:00 [accepted] PHST- 2020/03/22 06:00 [pubmed] PHST- 2021/03/10 06:00 [medline] PHST- 2020/03/22 06:00 [entrez] AID - jnumed.120.241737 [pii] AID - 10.2967/jnumed.120.241737 [doi] PST - ppublish SO - J Nucl Med. 2020 Nov;61(11):1615-1620. doi: 10.2967/jnumed.120.241737. Epub 2020 Mar 20.